We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Drug-Induced Torsades de Pointes and Genetic Screening

Amit Noheria, MBBS, SM1
[+] Author Affiliations
1Cardiovascular Division, Washington University School of Medicine, St Louis, Missouri
JAMA Intern Med. 2016;176(4):560-561. doi:10.1001/jamainternmed.2016.0070.
Text Size: A A A
Published online


To the Editor I read with great interest the Teachable Moment in a recent issue of JAMA Internal Medicine1 about QT prolongation and pulseless arrest due to Torsades de Pointes (TdP) attributed to inappropriate treatment with moxifloxacin.1 This adverse event occurred in setting of multiple risk factors for QT prolongation including age, female sex, mild hypokalemia, cardiomyopathy, and use of antipsychotic drug quetiapine.2 Both moxifloxacin and quetiapine inhibit the potassium channel (hERG/KCNH2) blocking the inwards potassium current (IKr) of the cardiac action potential and prolonging the QT interval.3,4 However, QT-prolonging drugs may not be solely responsible for TdP but rather unmask an underlying genetic predisposition to QT prolongation.2 Patients with drug-induced TdP have a 10% to 20% prevalence of long QT syndrome (LQTS) mutations or other genetic variants reducing their cardiac repolarization reserve.2,5 The presence of an LQTS-associated mutation has implications not only for the index patient but also first-degree relatives who might also be at an increased risk of sudden cardiac death with or without being challenged with QT-prolonging drugs. The Heart Rhythm Society and the European Heart Rhythm Association Expert Consensus Statement5 on genetic testing for channelopathies thus recommends that LQTS genetic testing should be considered for the patient with drug-induced TdP and importantly recommends that a 12-lead electrocardiogram be obtained in all first-degree relatives to screen for LQTS.5 This is an important teaching point to remember when we see patients whose genetic predilection for TdP is unmasked by QT-prolonging drugs.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





April 1, 2016
Arjun Gupta, MD; Ambarish Pandey, MD
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
2Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
JAMA Intern Med. 2016;176(4):561. doi:10.1001/jamainternmed.2016.0076.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...